IMEXHS Wins Public Tender in Mexico Adding $384,000 ARR

Major Public Sector Contract Boosts Recurring Revenue

IMEXHS Limited (ASX:IME) has secured a public tender contract to deploy its Aquila+ AI-driven radiology platform across 20 hospitals and clinics in Zacatecas, Mexico, generating $384,000 in new annual recurring revenue (ARR) alongside a $50,000 implementation fee. This deal, brokered through distributor partner GOBA, marks a notable expansion of IMEXHS’s footprint in the Mexican public healthcare system.

The contract’s scale and scope underscore IMEXHS’s growing ability to compete in public sector procurement, a critical arena for sustainable growth. The deployment will embed the company’s five proprietary AI workflow agents alongside two diagnostic algorithms from Gleamer; ChestView and Fracture Detection; forming one of the most comprehensive AI-integrated radiology rollouts in a public hospital network to date.

Technology Integration and Implementation Timeline

The Aquila+ platform’s AI agents automate radiology workflows, aiming to improve efficiency and diagnostic accuracy. The inclusion of Gleamer’s diagnostic algorithms adds specialized capabilities for chest imaging and fracture detection, enhancing clinical decision support across the network.

Implementation is underway and expected to complete by the end of June 2026, with full ARR contribution anticipated from September. This timeline aligns with IMEXHS’s broader strategy to accelerate software-driven revenue growth, complementing its recent performance where AI agents have been central to its operational expansion and profitability improvements. Notably, the company has reported strong momentum in Latin America, with contracts in Colombia and Peru contributing to a 13% revenue increase in Q1 FY26 and underpinning its AI-native platform pivot strong Q1 FY26 growth.

Strategic Implications for Mexico Expansion

This contract reinforces IMEXHS’s Mexico expansion strategy, a key focus market in Latin America. The company’s ability to win a multi-site public tender demonstrates competitive strength and positions it well for future tenders in the region’s public healthcare sector. It builds on a track record of delivering AI-powered radiology solutions that have driven recurring revenue growth and profitability, as evidenced in its FY25 results where ARR grew 16% and EBITDA tripled FY25 ARR growth.

While the deal’s financial terms are clear on ARR and implementation fees, the contract duration and broader revenue impact remain unspecified. The rollout’s success will be a key factor in assessing IMEXHS’s capacity to replicate such wins and scale its AI radiology platform across Latin America’s fragmented healthcare systems.